Best Practice & Research Clinical Haematology
Volume 24, Issue 4 , Pages 509-514, December 2011

Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?

  • Richard M. Stone, MD, Professor of Medicine (Director)

      Affiliations

    • Harvard Medical School, Boston, MA 02215, USA
    • Adult Leukemia Program, Dana-Farber Cancer Institute, 450 Brookline Avenue, M1b-17, Boston, MA 02215, USA
    • Corresponding Author InformationTel.: +1 617 632 2214; Fax: +1 617 632 2933.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1521-6926(11)00086-7

doi:10.1016/j.beha.2011.09.006

Best Practice & Research Clinical Haematology
Volume 24, Issue 4 , Pages 509-514, December 2011

Article Tools

* Image Usage & Resolution